Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Miller

Internal Medicine Dothan, AL Medical Doctor

NPI 1477528990 CMS profile 248564

1118 Ross Clark Cir, Suite 303, Dothan, AL 36301

Open in the dashboard

General payments

$13,829

869 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Miller of Dothan, AL is reported in the CMS Open Payments database as having received $13,829 across 869 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,574 90
2024 General $2,189 117
2023 General $1,995 125
2022 General $2,321 140
2021 General $2,017 143
2020 General $1,600 99
2019 General $2,134 155

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Miller
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Christopher Miller were reported at $1,574. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Christopher Miller Internal Medicine median Middle half National median
2019 $2,134 $159 $48–$570 $163
2020 $1,600 $119 $33–$402 $114
2021 $2,017 $135 $37–$521 $132
2022 $2,321 $141 $42–$496 $149
2023 $1,995 $149 $45–$519 $160
2024 $2,189 $154 $47–$537 $164
2025 $1,574 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,194 63 payments
  2. Amgen Inc. $1,101 84 payments
  3. Novo Nordisk Inc $1,033 72 payments
  4. AbbVie, Inc. $865 49 payments
  5. AstraZeneca Pharmaceuticals LP $847 50 payments
  6. Janssen Pharmaceuticals, Inc $673 54 payments
  7. Gilead Sciences, Inc. $611 36 payments
  8. Novartis Pharmaceuticals Corporation $591 44 payments
  9. Lilly USA, LLC $548 47 payments
  10. Merck Sharp & Dohme Corporation $545 44 payments
  11. Other $5,821 326 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,809 867 payments
  2. Education $20 2 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $766 54 payments
  2. Ozempic $729 58 payments
  3. TRELEGY ELLIPTA $704 39 payments
  4. XARELTO $637 53 payments
  5. Kerendia $502 25 payments
  6. FARXIGA $488 25 payments
  7. Repatha $488 41 payments
  8. Prolia $463 32 payments
  9. SHINGRIX $462 22 payments
  10. Vascepa $400 24 payments
  11. Other $13,128 878 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 148 drugs

Part D claims

8,449

Median for Internal Medicine: 777

Drug cost

$1,132,261

Median for Internal Medicine: $73,373

Branded share of claims

24.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 64 $276,056
Stribild Elviteg/Cob/Emtri/Tenofo Disop Brand 25 $113,386
Ozempic Semaglutide Brand 72 $100,044
Eliquis Apixaban Brand 57 $66,980
Jardiance Empagliflozin Brand 48 $65,522
Isentress Raltegravir Potassium Brand 15 $40,862
Mounjaro Tirzepatide Brand 22 $37,994
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 31 $37,660
Januvia Sitagliptin Phosphate Brand 37 $35,118
Myrbetriq Mirabegron Brand 31 $30,853

The 10 drugs with the highest cost, of 148 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 139 billing codes

Paid by Medicare

$281,156

Of which drugs: $47,540

Medicare patients

1,059

Average age 75

Services billed

20,022

554 women, 505 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 43%
Ischemic heart disease 42%
Chronic kidney disease 40%
Atrial fibrillation 34%
Heart failure 33%
Depression 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 15 900 $17,129
Vaccine for influenza for injection into muscle 90662 Office 116 116 $8,520
Injection, methylprednisolone acetate, 1 mg J1010 Office 19 1,600 $160
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 24 106 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$295 — —
TRELEGY ELLIPTA
$153 31 —
SHINGRIX
$138 47 —
QULIPTA
$126 — —
Repatha
$109 34 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

869 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record